A Phase Ii Biomarker-Driven Study Evaluating The Clinical Efficacy Of An Mdm2 Inhibitor, Milademetan, In Patients With Intimal Sarcoma, An Ultra-Rare Cancer With Highly Life-Threatening Unmet Medical Needs (Ncch1806/Mk004)
ANNALS OF ONCOLOGY（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要